Background. Progressive graft dysfunction (GDF) and loss of insulin independence (II) have been invariably observed in islet transplant recipients under the "Edmonton protocol." To reestablish II, we performed supplemental islet infusions (SI) in recipients of allogeneic islet transplant alone, displaying GDF. To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial. Methods. Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; nϭ5) or with EXN and etanercept treatment (SI-EXN; nϭ4). Clinical and metabolic profiles were assessed during 18-month follow-up. Results. Long-term II (18 months) was observed in 100% of SI-EXN and in 20% of SI-control (Pϭ0.04). SI-EXN subjects demonstrated restoration of function better than that seen after initial islet infusions. Comparison of SI-EXN and SI-control groups demonstrated better responses in SI-EXN subjects at 3 months post-SI. During the 18 months of follow-up, function was sustained in the SI-EXN subjects better than in SI-controls. Acute effects of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved first and second phase insulin release in response to intravenous glucose tolerance test and suppressed postprandial hyperglucagonemia after mixed meal tolerance test. Conclusion. These results suggest that the combination of EXN and etanercept improve engraftment and long-term islet survival and function in subjects undergoing SI. This data, however, must be interpreted with some caution because of small sample size, lack of randomization, and sequential comparison with historical controls.
A current limitation of islet transplantation (ITx) under the "Edmonton protocol" is that insulin independence (II) is not sustained and exogenous insulin reintroduction is required in virtually all ITx recipients over time to maintain normoglycemia (1) (2) (3) (4) . Despite graft dysfunction (GDF), benefits of stable control, lack of severe hypoglycemia (3) , and improved quality of life remain (5) .
To maintain these benefits and to reestablish II in subjects already on immunosuppression, supplemental islet infusions (SI) have been performed at our center in ITx recipients with GDF (4) ; results demonstrated some success. Recently, two new agents, exenatide (EXN) and etanercept, became available that warranted testing in ITx.
Exenatide, like GLP-1 and its analogues enhances glucosestimulated insulin secretion and inhibits glucagon secretion (6, 7) . In experimental models, GLP-1 analogues protected islet ␤ cells from stress and immunosuppressive drug-induced apoptosis in vitro and in vivo (8, 9) . In rodents, they promoted pancreatic progenitor cell differentiation and improved ␤-cell function and viability (10 -12) . In human ITx recipients, islets responded to GLP-1 treatment during glucose challenge (13) . In two other groups, EXN administration in ITx recipients with GDF resulted in improved responses to glucose and meal challenges and reduction in exogenous insulin requirements or maintenance of II (14, 15) . Hence, EXN has the potential to improve existing islet function, prevent loss of functional islet mass and possibly even stimulate islet regeneration.
Etanercept is a dimeric fusion protein consisting of the extracellular binding portion of the human tumor necrosis factor receptor linked to the Fc portion of human IgG1. Etanercept binds and deactivates tumor necrosis factor-alpha, a key regulator of inflammatory immune responses and has been shown to be toxic to human ␤ cells (16) . Etanercept in rodent models improved functional outcome of marginal mass islet allografts (17) . In human islet allotransplantation, its use was associated with II in two different marginal mass studies; one combined with antithymocyte globulin and daclizumab (18) and another with EXN (19) . Hence, using etanercept to decrease the inflammatory response from the ITx procedure and promote better islet engraftment has the potential to improve short-and long-term islet survival and function.
The aim of this study was to assess the impact of EXN and etanercept as part of the peri-transplant induction regimen, and long-term EXN administration, on islet engraftment and short and long term function in subjects undergoing SI.
MATERIALS AND METHODS

Definitions
Islet transplant completion: Achievement of II after sequential ITx usually observed after two islet infusions. At 3-month post-completion the best function after ITx is generally observed in II subjects with stable glycemic control (20) .
Graft Dysfunction: C-peptide positivity, but, elevation of fasting capillary glucose more than 140 mg/dL or 2-hr postprandial capillary glucose more than 180 mg/dL on three or more occasions in a week, or two sequential monthly HbA1c values more than 6.5% (21) .
Insulin independence: C-peptide positivity and absence of GDF.
Supplemental Islet Infusions (SI): Additional single islet infusion performed in subjects with GDF.
This study was a non-randomized pilot clinical trial. The protocols were approved and monitored by the institutional review board and signed informed consent was obtained from all subjects.
Historical subjects (SI-control) consisted of five islet recipients transplanted in an Edmonton-like protocol as previously described (4) . The EXN subjects (SI-EXN) consisted of one subject from this same protocol and three subjects from the Immune Tolerance Network (ITN) protocol (2) . These subjects were commenced on daily EXN treatment for GDF and were eligible for SI if they did not re-achieve II after 3 months of treatment. Follow-up until 18 months post-SI was completed by all subjects.
The primary outcome was the reestablishment of II after SI with etanercept/daclizumab induction and prolonged EXN treatment.
To see if SI outcomes were comparable with initial islet infusion outcomes, metabolic data at 3 months postsupplemental and initial islet infusions (completion) were compared.
Subjects with GDF were commenced on subcutaneous EXN (Byetta, Amylin Pharmaceuticals, Inc., San Diego, CA and Eli Lilly and Company, Indianapolis, IN), as described (15) . Median dose was 17.5 g (range 10 -25 g) for a median time of 171 days (range 155-197) before SI. One hour before SI, a single EXN dose was administered subcutaneously (median 5, range 5-10 g). After SI, each subject continued EXN at pre-SI levels (Table 1) , and subsequently doses were adjusted as necessary as dictated by clinical condition.
Islets were processed as described (22, 23) . Initial islet transplants were performed as previously described (2,4), the main difference being fresh (ITN) versus cultured islets.
In SI-control group, for SI, induction consisted of daclizumab (Zenapax, Roche, Nutley, NJ) 1 mg/kg biweekly for five doses starting at transplant. This was continued monthly in first year and bimonthly in second year. Maintenance immunosuppressive drugs consisted of tacrolimus (Prograf, Astellas Pharma US, Inc., Deerfield, IL) and sirolimus (Rapamune, Wyeth Pharmaceuticals, Inc., Madison, NJ) (4, 24) .
In SI-EXN subjects, induction and maintenance immunosuppression was the same as SI-control subjects, except for administration of EXN and etanercept (Enbrel, Immunex Corporation, Thousand Oaks, CA). Etanercept dosage was 50 g intravenously (IV) 1 hr pretransplant then 25 g subcutaneously twice a week for 2 weeks. Daclizumab induction consisted only of initial five doses.
Mixed meal tolerance test (MMTT, 5 hr) and intravenous glucose tolerance test (IVGTT) (15, 21) without EXN injection were performed during follow-up visits every 3 months to assess graft function. In SI-EXN group, additional MMTT with EXN was performed to evaluate its acute effects. Exenatide was administered 1 hr before MMTT on the first day and then discontinued entirely until MMTT without EXN, typically performed on the third day of the visit.
To evaluate if acute administration of EXN could improve first phase insulin release (FPIR), IVGTT with and without EXN administration before the tests were performed at the 15-month follow-up visit.
Statistical Analysis
Baseline characteristics were compared between SI-EXN and SI-control groups with two-tailed t tests. KaplanMeier survival curves were used to assess II duration in the two groups. Insulin-independence duration at 12 and 18 months post-SI was compared with an exact two sample test of proportions. For each metabolic and clinical outcome measure, a linear mixed model regression was fit to the data to estimate and compare mean response values corresponding to all acute and chronic assessments of interest. This method generalizes linear regression techniques allowing for repeated observations by taking into account correlation within observations from the same subject to more appropriately estimate variances used in tests of significance. Therefore, we can si-multaneously estimate and compare inter-and intragroup differences over time while appropriately accounting for within subject correlation. Similarly, we can estimate differences between MMTT performed with and without EXN at 3 to 12 and 18 months of follow-up and between IVGTT performed with and without EXN at 15 months follow-up.
Post-SI IVGTT and MMTT results were compared with 3 months postislet completion period. Results are expressed as meanϮSE, a P value less than 0.05 was considered statistically significant.
RESULTS
Subject Characteristics
SI-control and SI-EXN groups showed similar baseline characteristics except for II duration after initial islet infusion(s), 221Ϯ58 vs. 648Ϯ34 days, respectively, P less than 0.001 and GDF duration before SI, 326Ϯ93 vs. 664Ϯ83 days, Pϭ0.03 (Table 1 ). All subjects in both groups showed negative T-cell crossmatch pre-SI and negative panel-reactive antibody pre-and post-SI. The mean human leukocyte antigen class I and II mismatch/human leukocyte antigen repetition among donors were similar. The SI-control and SI-EXN groups received mean of 8713Ϯ2123 and 5613Ϯ485 islet equivalents/kg, respectively (Pϭ0.25). There were no significant differences in donor characteristics, cold ischemia time, or perfluorocarbon use. Islet isolation techniques were comparable. Main difference was that for SI-control group, DNAase (0.625 mL/L, Pulmozyme [dornase alfa] recombinant Genentech, Inc., San Francisco, CA) was used throughout the isolation procedure including digestion, dilution, and wash. For SI-EXN group, DNAase was only used during the digestion inside Ricordi chamber, whereas heparin (10 units/ mL, Heparin, Sodium, American Pharmaceutical Partners, Schaumberg, IL) was used throughout isolation procedure. Digestion was performed with Liberase enzyme blend (Roche Pharmaceuticals, Basel, Switzerland) in both groups. Islets were cultured in both groups. Islet viability and stimulation index were not different in both groups. IV heparin was given in the infusion bag in both groups (4) . There were no differences in peritransplant insulin regimen. No group received IV insulin therapy. Immunosuppressive drug levels were comparable during the study.
Baseline metabolic function was similar between the two groups before SI. Pre-SI mixed meal tolerance testing showed comparable AUC Glucose(53,489Ϯ6,084 vs. 45,714Ϯ4,407 mg/ min/dL; Pϭ0.36) and AUCC-peptide (596Ϯ48 vs. 619Ϯ139 ng/ min/mL; Pϭ0.86) in SI-control and SI-EXN groups, respectively. SI-EXN data are that obtained 48 hrs after being off EXN injections.
Insulin Independence and Clinical Outcomes
Insulin independence was achieved in 3 of 5 (60%) SIcontrol and 4 of 4 (100%) SI-EXN subjects. By 18 months only 1 out of 4 (20%) of SI-control subjects were II compared with 100% in SI-EXN group (Pϭ0.04). Comparison of the survival curves illustrating II for these groups suggests significantly longer duration of II during the 18 months follow-up post-SI in the EXN group, compared with SI-control (Pϭ0.025) (Fig. 1) .
With development of GDF post-SI, HbA1c in SI-control group increased with time and was no longer different to pre-SI at 12 and 18 months (Table 1) . In contrast, improvement in HbA1c in SI-EXN group was sustained throughout follow-up (HbA1c decrement 0.48%-1.2%, PϽ0.05).
SI-EXN subjects experienced nausea of varying degrees at the beginning of EXN administration (pre-SI) (15) . After SI, no side effects related to EXN or etanercept were reported. Subjects were tolerating EXN well. Body weight was stable throughout the study period.
Metabolic and Hormonal Responses to Stimulation Testing
Intravenous Glucose Tolerance Test
Up to 9 months post-SI acute insulin response to glucose (AIRg) in SI-EXN group was similar to that observed at 3 months post-completion of the initial islet transplant (20.8Ϯ0.9 vs. 19Ϯ2.9 U/mL, respectively, Pϭ0.55). Over time (Table 2) , AIRg values in the absence of EXN before the test were 10.2Ϯ3.2, 9.6Ϯ2.3, and 11.7Ϯ1.7 U/mL at 12, 15, and 18 months, respectively.
Mixed Meal Tolerance Test
A significant and sustained increase in peak and AUCCpeptide responses to MMTT in SI-EXN group was observed at all time points (PϽ0.002) (Fig. 2) whereas AUCC-peptide in SI-control (680Ϯ86 ng/min/mL) was not different from pre-SI (596Ϯ43 ng/min/mL). SI-EXN subjects demonstrated higher AUCC-peptide at 3, 9, and 15 months than SI-control (PϽ0.01). AUCC-peptide in SI-EXN 3 months post-SI (1024Ϯ75 ng/min/ mL) was higher than 3 months postislet transplant completion (708Ϯ48 ng/min/mL PϽ0.001) and pre-SI (620Ϯ121 ng/min/ mL, PϽ0.001). To correct for glucose levels, the ratio of the AUCC-peptide-to-AUCGlucose, namely mixed meal stimulation index (MMSI) (25) was calculated. Significant and sustained increase in MMSI was observed in SI-EXN group throughout time (PϽ0.01) ( Table 2 ). In SI-control group, an increase in MMSI was only observed at 3 to 9 months as compared with pre-SI (PϽ0.03). Amylin levels in SI-EXN group followed the same pattern as C-peptide values (Fig. 3) . The abnormal glucagon secretion observed pre-SI was ameliorated by chronic EXN administration. AUCGlucagon at 6 and 15 months were 15,407Ϯ2,988 and 16,929Ϯ1,627, respectively, vs. 21,812Ϯ 888 pg/min/mL pre-SI (PϽ0.03).
Fasting plasma glucose post-SI in both groups was not different from pre-SI. AUCGlucose was significantly decreased at 3 to 18 months in SI-control (PϽ0.026) and 3 to 15 months in SI-EXN (PϽ0.029). AUCGlucose was not significantly different between groups (Fig. 2) .
Note that the comparison was made with mixed meal tests without EXN and off for 48 hrs.
Effects of Acute Exenatide Administration
We observed improvement of first and second phase insulin release in the SI-EXN group, when EXN was administered 1 hr before the IVGTT at 15 months (AIRg 20.6Ϯ4.2 vs. 9.6Ϯ2.3 U/mL, Pϭ0.02; AUC insulin at 10 -60 min 1117Ϯ189 vs. 584Ϯ74 U/min/mL, Pϭ0.036 with and without EXN, respectively) (Fig. 3) . This was accompanied by faster glucose disappearance rate (K30 Ϫ1.65%/min vs. Ϫ0.95%/min, Pϭ0.03, with and without EXN, respectively). Acute EXN administration resulted in suppression of the abnormal glucagon response during MMTT (Fig. 3) . The post-prandial glucose rise was also prevented. C-peptide and amylin responses were delayed and diminished and followed glucose. These changes were maintained up to 18 months post-SI.
DISCUSSION
SI is a potential solution for GDF provided that further islet loss can be prevented. At our center, SI were performed in five subjects in an Edmonton-like protocol with some success (4). The rationale then was to see if restoring islet mass to greater than marginal levels can result in longer duration of II. Although II could be restored in many subjects, it deteriorated over time similar to that seen with initial islet infusions. With the emergence of EXN and etanercept, better islet survival was potentially possible and since subjects in these protocols were already immunosuppressed they were considered a good group to test these agents.
Administration of these two agents at time of SI resulted in significantly improved short-and long-term outcomes, notably all subjects were II by 18 months in SI-EXN group, compared with only one in SI-control group.
Limitations of this study are the small sample size and the nonrandomized sequential comparison of SI-EXN with historical controls that may lead to differences between the two groups that affect outcomes. Indeed, SI-EXN subjects had longer duration of both II and GDF after initial infusions, however, the groups were equal in their metabolic testing suggesting functional ␤-cell mass should be comparable.
Similarly, evaluation of the islet product in both groups demonstrated minor differences in islet preparation techniques, however, islet equivalents/kilogram, viability, and stimulation index were not significantly different in the two groups. Metabolic testing in the SI-EXN groups post-SI demonstrated that not only was transplant function restored to the best it had ever been, it was even better with superior responses to both mixed meal and intravenous glucose stimuli (i.e., significantly higher and sustained C-peptide responses were observed after MMTT; and up to 9 months, insulin secretion in response to IV glucose was sustained). In addition, at 15 months, acute EXN administration was able to restore first and second phase insulin release. These show improved ␤-cell secretory capacity similar to that observed after EXN administration in patients with type 2 diabetes (26, 27) . In contrast, EXN treatment of ITx recipients with existing GDF (14, 15, 19) or marginal mass ITx did not restore FPIR (14, 19) suggesting that FPIR is dependent on certain number of functional islets. Treatment with EXN should be more effective if administered at the time of initial islet infusions and continued chronically.
The greater achievement of II in SI-EXN group may be due to prevention of apoptosis, protection from immunosuppressive-mediated toxic effects (8, 9, 28) at time of islet infusion, thereby improving engraftment. These same effects of EXN, plus its ability to improve glycemic control through glucagon secretion suppression and reduced gastric emptying may explain the long-term functional improvement.
Finally, the possibility of increased islet regeneration induced by GLP-1 analogues (10 -12) has been demonstrated in animal models, but remains to be proven in human studies and until islet mass can be accurately measured will likely remain elusive. The current preparation of EXN with its side effects may limit the use in some patients.
These data do not allow differentiation between the effects of etanercept and EXN. Etanercept administration at peritransplant and early posttransplant period may have contributed to better islet engraftment resulting from its antiinflammatory effects (18, 19) , a synergistic effect with EXN cannot be excluded. It is unlikely that etanercept had a significant impact in the long-term effects observed, except for an increased islet mass at outset.
Abnormal postprandial hyperglucagonemia has been documented in subjects with diabetes (29 -31) . We confirmed post-prandial hyperglucagonemia in this ITx population also. Acute EXN administration resulted in significant suppression in glucose and glucagon elevation during MMTT. These effects were sustained throughout the period of follow-up. C-peptide and amylin were also suppressed, likely due to near normal glucose levels, secondary to EXN related glucagon suppression and decreasedgastric emptying (32) .
As mentioned above there are important limitations to this study; these observations will be evaluated in a prospective randomized controlled fashion in the Imminent Clinical Islet Transplant Consortium trial.
Based on the 18-month data collected so far, it seems that the effects of EXN plus etanercept treatment on SI grafts are beneficial in sustaining long-term islet survival and function thereby improving the outcomes of ITx. Further benefits could be gained from the use of EXN at all stages of islet preparation, transplantation, and follow-up. This could result in even greater effects on engraftment and long-term islet allograft function and may even allow for more consistent achievement of sustained II after single donor ITx.
